by Peter Ciszewski | Aug 30, 2023
The U.S. Food and Drug Administration (FDA) has approved luspatercept (Reblozyl) as first in line therapy for anemia in adult patients with myelodysplastic syndromes (MDS). More specifically, the drug is approved to treat anemia without previous erythropoiesis...
by Peter Ciszewski | Aug 26, 2023
The U.S. Food and Drug Administration (FDA) has approved pozelimab (Veopoz) to treat persons one year and older with complement hyperactivation, angiopathic thrombosis, and protein-losing enteropathy, also known as CHAPLE disease. CHAPLE disease is a genetic...
by Peter Ciszewski | Aug 17, 2023
The US Food and Drug Administration (FDA) has approved of palovarotene (Sohonos) to treat fibrodysplasia ossificans progressiva (FOP). More specifically, the orphan drug is indicated to treat the reduction in volume of new heterotopic ossification in females aged 8...
by Peter Ciszewski | Aug 14, 2023
The US Food and Drug Administration (FDA) has given accelerated approval to elranatamab-bcmm (Elrexfio) to treat adults with relapsed or refractory multiple myeloma. More specifically, it is approved for those who have received at least four prior lines of therapy,...
by Madaline Spencer and Peter Ciszewski | Jul 27, 2023
Courtney Silverthorn, Ph.D., Associate Vice President for Science Partnerships at the Foundation for the National Institutes of Health (FNIH), discusses the recent announcement that the Accelerating Medicines Partnership Bespoke Gene Therapy Consortium (AMP BGTC) has...
